Early Results of First In Vivo Gene-Editing Trial Encouraging

Two patients who received Sangamo's zinc finger-based treatment for Hunter syndrome have lower biomarkers of the condition, but no signs of new enzyme production.

Source: The Scientist - September 5, 2018 Category: Science Tags: News & Opinion Source Type: news